Clinical observation of trans-artery infusion chemotherapy with carboplatin or cisplatin in advanced non-small-cell lung cancer

Objective: To evaluate the effect of trans-artery infusion chemotherapy with carboplatin in advanced non-small-cell lung cancer. Methods: Fifty-two patients with advanced non-small-cell lung cancer pathologically confirmed were treated by trans-artery chemotherapy. They were divided into Carbo group and CDDP group according to anti-cancer drug. The effectiveness of treatment and complication were observed respectively, χ2 test was applied for statistical analysis. Results: There were 27 patients in Carbo group and 25 in CDDP group. In Carbo group, 15 had partial remission (PR), 8 were stable (S) and progression (P) was observed in 4. A responsive rate of 55.6% was obtained. In CDDP group, 15 cases showed rumor partial remission (PR), 7 were stable (S) and 3 were progression (P). The responsive rate was 60%. There was no statistical significance between them (P>0.05). There was no statistical significance in incidence rate of myelosuppression, nausea and vomiting between Carbo group and CDDP group (P>0.05). Conclusion: Compared with CD- DP, trans-artery infusion chemotherapy with Carbo has no better therapeutic effect and no less adverse effects. We maintain CDDP as anti-cancer drag when we perform arterial infusion chemotherapy of advanced non-small-cell lung cancer. (authors)